Structural Heart Imaging Market is segmented By Imaging Modality(Echocardiogram,Angiogram(CT and MRI)), By Procedure Type(Transcatheter Aortic Valve Replacement (TAVR), Surgical Aortic Valve Replacement (SAVR), Transcatheter Mitral, Valve Repair (TMVR), Left Atrial Appendage Closure (LAAC), Annuloplasty, Valvuloplasty, Others), By Application (Diagnosis and Surgery), By End user (Hospitals, Specialty Clinics, Cardiac Centers, Diagnostic Centers, Ambulatory Surgical Centers and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Market Overview
The structural heart imaging market size was valued at USD 14085.8 mn in 2022, projected to reach USD 34912.46 mn by 2030, growing at a CAGR of 12.4% during the forecast period (2023-2030).
Structural heart imaging (SHI) is a cardiology field that deals with valvular and non-valvular heart disease. SHI is a molecular imaging technology that is used to screen the heart. This method entails using high-resolution cameras to create different images of the heart's inner components, which aid in the proper diagnosis of the patient's condition. The two most popular imaging techniques that closely analyze the heart structure to reveal narrowing or blockage of blood arteries are echocardiograms and angiography (MRI, CT, etc.)
Market Scope
Metrics |
Details |
Market CAGR |
12.4% |
Segments Covered |
By Imaging Modality, By Procedure Type, By Application, By End user, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
Market Dynamics
Significant advances in structural heart interventions are expected to drive market growth.
Structural heart disease intervention is a game-changing breakthrough that has already displaced open surgery and enabled the treatment of a larger number of patients at a reduced cost. Significant progress has been made in structural cardiac interventions over the previous decade. The advancements in interventions and imaging are inextricably linked, from transcatheter aortic and pulmonic valve replacement to left atrial appendage occlusion procedures, percutaneous mitral repair techniques, and, more recently, transcatheter mitral valve replacement and tricuspid interventions. The commercial availability of 3-dimensional (3D) echocardiography, for instance, improved the efficiency, precision, and adaptability of the edge-to-edge repair technique. The collaboration of ultrasound and device firms continues to fuel breakthroughs in imaging that can then assist drive device innovation, thanks in part to imaging groups like the American Society of Echocardiography. Because of the imaging-intensive nature of all of these procedures, imagers must be familiar with a wide range of anatomical targets, modern imaging techniques, and the execution of numerous procedural interventions. Imagers have proven crucial to the field's continuous progress due to this information foundation. Thus, the market is expected to drive in the forecast period from the above statements.
Restraint:
Strict regulatory guidelines for equipment used in structural heart imaging, a lack of awareness regarding cardiac-specific structural imaging, and higher costs are some of the factors due to which the market is expected to hamper the market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 patients often have symptoms and signs of a respiratory tract infection, although cardiac manifestations, such as indicators of myocardial damage, are also prevalent. Myocardial injury in COVID-19 can be caused by an oxygen supply-demand imbalance resulting from hypoxia, hypoperfusion, tachycardia, microvascular and macrovascular thrombosis, or inflammation-related injury (especially in the setting of underlying structural heart disease or coronary atherosclerosis). Imaging aids in the early detection of disease in individuals with underlying cardiovascular disorders and the detection of cardiovascular consequences in people who have already been infected with SARS-CoV-2. Although symptoms of cardiac failure can be easily diagnosed using chest radiography, chest CT, and echocardiography, the best way to examine myocardial injury is with a cardiac MRI.
Moreover, the growing body of evidence indicating a high prevalence of cardiac involvement in COVID-19 patients warrants MRI in this patient population. In contrast, there is physical contact during imaging of the Covid-19 patients. Therefore, there are chances of spreading the virus, and the government has come out with guidelines during imaging(MRI, CT, and others). Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.
Segmentation Analysis
Angiogram segment is expected to hold the largest market share in the structural heart imaging market
The angiogram segment is expected to dominate in 2020. The segment's growth is benefited because demand for various imaging modalities is projected to rise as the need for diagnostic and effective imaging for detecting SHDs, particularly CHDs, grows. Moreover, Angiogram is further segmented into MRI and CT. In the anatomic and functional evaluation of cardiovascular disease, MRI is a critical diagnostic technique. 2D phase-contrast (2D-PC) MRI has been used in several procedures for blood flow quantification. Flow in four dimensions MRI is a volumetric acquisition that records the vector field of blood flow and anatomic pictures in a time-resolved manner. Compared to 2D-PC, it also makes acquisition easier and allows for a more precise and thorough hemodynamic assessment. With advancements in accelerated imaging, 4D flow MRI scanning times have been greatly reduced while image quality has been maintained, allowing this technology to move from research to everyday clinical practice. 4D flow MRI will likely become an essential component of cardiac imaging in practices dealing with congenital and acquired structural heart disease as experience grows, and 4D flow sequences and postprocessing software become more widely available.
Moreover, the use of advanced parallel imaging techniques like k-t GRAPPA has resulted in scan times that are more realistic, such as 8-12 minutes for 4D flow MRI of the aorta and 10-20 minutes for complete heart coverage. As a result, using 4D flow MRI in a clinical setting has become increasingly practicable, as seen by an increase in recent reports on the technique's utility in patient studies for measuring cardiac and vascular hemodynamics. Thus, the market is expected to hold the largest market share in the forecast period.
Geographical Analysis
North America region holds the largest market share in the global structural heart imaging market
In 2020, North America accounted for the highest revenue share. The increasing prevalence of Congenital heart defects, increasing demand for technologically improved technologies for the treatment of Structural Heart Disease, increased lifestyle change adoption, increased structural disease awareness, more preventative care, favorable government policies, clinical trials, and product launches by the key players in the region are some of the factors due to which the market is expected to boost in the forecast period.
For instance, according to the Centers for Disease Control and Prevention, The most frequent birth defects are congenital heart defects (CHDs), and babies are born with these problems. CHDs affect nearly 1% of―or about 40,000―births per year in the United States. Some CHDs, particularly mild forms, is growing in prevalence (the number of kids born with a heart defect divided by the total number of births), while the prevalence of other types has remained consistent. A ventricular septal defect is the most frequent type of heart abnormality (VSD). About 1 in 4 babies with CHD have a critical CHD. Infants with critical CHDs generally need surgery or other procedures in their first year of life.
Moreover, NuVera Medical, Inc. announced positive results from its non-randomized, single-center First-In-Human (FIH) study in October 2020, which looked at the NuVision ICE Catheter's feasibility in visualizing anatomical structures in patients undergoing structural heart procedures such as mitral or tricuspid valve repairs or LAAC. With improved 4D ICE imaging, the business hopes to improve the efficacy of transcatheter cardiac treatments. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Competitive Landscape
Major key players in the structural heart imaging market are;
- Boston Scientific Corporation
- Circle Cardiovascular Imaging Inc
- Absolute Medical Services, Inc.
- Pie Medical Imaging B.V
- Siemens Healthineers GmbH
- Cardinal Health Inc
- Koninklijke Philips NV
- GE HealthCare
- Neusoft Medical Systems
- Shimadzu Corporation